| scholarly article | Q13442814 |
| P50 | author | Rene E Toes | Q42494390 |
| P2093 | author name string | Breedveld FC | |
| van Venrooij WJ | |||
| de Jong BA | |||
| Verweij CL | |||
| Huizinga TW | |||
| van Gaalen FA | |||
| Linn-Rasker SP | |||
| P2860 | cites work | The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin | Q32133798 |
| Evaluating diagnostic tests with imperfect standards | Q38140577 | ||
| P433 | issue | 3 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| autoantibody | Q785022 | ||
| P304 | page(s) | 709-715 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study | |
| P478 | volume | 50 |
| Q36094049 | A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. |
| Q33300467 | A case-control study of rheumatoid arthritis identifies an associated single nucleotide polymorphism in the NCF4 gene, supporting a role for the NADPH-oxidase complex in autoimmunity |
| Q36815454 | A chronic model of arthritis supported by a strain-specific periarticular lymph node in BALB/c mice |
| Q81972128 | A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis |
| Q35555382 | A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population |
| Q29417125 | A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides |
| Q35868959 | A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis |
| Q50459617 | A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. |
| Q40513802 | A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease |
| Q35207886 | A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis |
| Q37087771 | A transmembrane polymorphism in FcgammaRIIb (FCGR2B) is associated with the production of anti-cyclic citrullinated peptide autoantibodies in Taiwanese RA. |
| Q39061558 | Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study |
| Q38257776 | Abnormal antibodies: what do you do? |
| Q82831163 | Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis |
| Q34190363 | Anti-CCP antibodies: the past, the present and the future |
| Q35067205 | Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis |
| Q37083382 | Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis |
| Q38855074 | Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis |
| Q24816803 | Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis |
| Q41836190 | Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1 shared epitope alleles. |
| Q86351640 | Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity |
| Q38857820 | Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review |
| Q61958824 | Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? |
| Q37898025 | Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. |
| Q53132137 | Anti-citrullinated protein antibodies activated ERK1/2 and JNK mitogen-activated protein kinases via binding to surface-expressed citrullinated GRP78 on mononuclear cells. |
| Q34367709 | Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis |
| Q43137492 | Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production |
| Q35994186 | Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. |
| Q38078245 | Anti-citrullinated protein antibodies: role in pathogenesis of RA and potential as a diagnostic tool |
| Q54215892 | Anti-citrullinated protein antibody response after primary EBV infection in kidney transplant patients. |
| Q34635933 | Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts |
| Q87375972 | Anti-cyclic citrullinated peptide (CCP) antibody in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) without rheumatoid arthritis |
| Q46351758 | Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy |
| Q37358171 | Anti-cyclic citrullinated peptide antibodies in children with Juvenile Idiopathic Arthritis |
| Q39039199 | Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis |
| Q36790337 | Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. |
| Q40375105 | Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis |
| Q54518407 | Anti-cyclic citrullinated peptide antibody is associated with radiographic erosion in rheumatoid arthritis independently of shared epitope status. |
| Q92122487 | Anti-cyclic citrullinated peptide antibody predicts the development of rheumatoid arthritis in patients with undifferentiated arthritis |
| Q36903191 | Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study |
| Q34594429 | Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis |
| Q35636880 | Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation |
| Q43195995 | Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis |
| Q34650192 | Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis |
| Q36740473 | Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis |
| Q80689354 | Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis |
| Q41680856 | Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection |
| Q64122268 | Antibody-dependent and -independent mechanisms of inflammatory arthritis |
| Q39042536 | Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity. |
| Q81664325 | Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: clues to disease pathogenesis |
| Q35554779 | Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? |
| Q35953226 | Arthritis of the large joints - in particular, the knee - at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis |
| Q40616388 | Association of PDCD1 polymorphism to Systemic Lupus Erythematosus and Rheumatoid Arthritis susceptibility |
| Q38153117 | Australian and New Zealand national evidence-based recommendations for the investigation and follow-up of undifferentiated peripheral inflammatory arthritis: an integration of systematic literature research and rheumatological expert opinion |
| Q36787717 | Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools |
| Q92034749 | Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology |
| Q24798609 | Autoantibodies in normals--the value of predicting rheumatoid arthritis |
| Q50879987 | Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. |
| Q36086129 | Autoantibodies to citrullinated proteins: ACPA. |
| Q37693939 | Autoantibodies to posttranslational modifications in rheumatoid arthritis |
| Q36086114 | Autoantibodies-the smoke and the fire |
| Q34290839 | Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis |
| Q35555021 | Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis |
| Q38177181 | Autoantibody-mediated bone loss |
| Q33399866 | Autoimmune responses in the rheumatoid synovium. |
| Q34159040 | Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. |
| Q84767437 | B cells in autoimmunity |
| Q38163603 | B cells participate in tolerance and autoimmunity through cytokine production |
| Q47314399 | Biomarkers in connective tissue diseases |
| Q55451002 | Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures. |
| Q39761544 | Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis |
| Q36330366 | CCR6(+) Th cell populations distinguish ACPA positive from ACPA negative rheumatoid arthritis |
| Q24801080 | Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis |
| Q37894283 | Citrullination of autoantigens: upstream of TNFα in the pathogenesis of rheumatoid arthritis. |
| Q36365784 | Citrullination only infrequently impacts peptide binding to HLA class II MHC |
| Q43641775 | Clinical features and disease outcomes of undifferentiated arthritis in Thailand |
| Q81190172 | Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study |
| Q84040588 | Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis |
| Q35866300 | Contribution of Peptide Backbone to Anti-Citrullinated Peptide Antibody Reactivity |
| Q40975154 | Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis |
| Q35470652 | Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. |
| Q35907747 | Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis |
| Q85653646 | Determination of Anticyclic Citrullinated Peptide Based on Biotin-Streptavidin-Amplified Time-Resolved Fluoroimmunoassay |
| Q36395509 | Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis |
| Q24675281 | Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review |
| Q36226393 | Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis |
| Q37453967 | Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. |
| Q82573398 | Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis |
| Q35808002 | Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis |
| Q84708012 | Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis |
| Q81415894 | Does DMARD treatment slow or prevent development of RA in patients with UA? |
| Q80167126 | Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'? |
| Q53668453 | Early prediction of rheumatoid arthritis by magnetic resonance imaging in the absence of anti-cyclic citrullinated peptide antibodies and radiographic erosions in undifferentiated inflammatory arthritis patients: a prospective study. |
| Q80579688 | Early rheumatoid arthritis in Italy: study of incidence based on a two-level strategy in a sub-area of Florence (Scandicci-Le Signe) |
| Q51647437 | Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study. |
| Q34460622 | Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis |
| Q41940757 | Enhanced MRI in early undifferentiated oligoarthritis of the knee joints: improvements already visible after 2 months of DMARDs treatment |
| Q40513222 | Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study |
| Q90241455 | Epitope Specificity of Anti-Citrullinated Protein Antibodies |
| Q33392167 | Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data |
| Q90696631 | Exacerbation of symptomatic arthritis by cigarette smoke in experimental arthritis |
| Q43661708 | Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody |
| Q42874449 | Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis |
| Q37873802 | Genetics of rheumatoid arthritis: what have we learned? |
| Q35311994 | Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss |
| Q39427587 | HLA class II and rheumatoid arthritis: the bumpy road of revelation |
| Q42412117 | HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets |
| Q44922542 | High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. |
| Q47549698 | Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands-Relation to Rheumatoid Arthritis. |
| Q92006207 | IL-6-PAD4 axis in the earliest phase of arthritis in knock-in gp130F759 mice, a model for rheumatoid arthritis |
| Q24813085 | Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis |
| Q87560405 | Identification of potential serum biomarkers for rheumatoid arthritis by high-resolution quantitative proteomic analysis |
| Q45282202 | IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin |
| Q90665188 | Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody-Positive Patients Without Rheumatoid Arthritis |
| Q87431443 | In palindromic rheumatism, hand joint involvement and positive anti-CCP antibodies predict RA development after 1 year of follow-up |
| Q24812914 | Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomerase |
| Q35913720 | Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin |
| Q46760849 | Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment |
| Q38618883 | Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review |
| Q35070446 | Infliximab: 12 years of experience |
| Q33923415 | Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor |
| Q35638730 | Influence of human leucocyte antigen-DRB1 on the susceptibility to rheumatoid arthritis and on the production of anti-cyclic citrullinated peptide antibodies in a Portuguese population |
| Q35556014 | Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis |
| Q85206758 | Is It Necessary to Combine Detection of Anticitrullinated Protein Antibodies in the Diagnosis of Rheumatoid Arthritis? |
| Q80167129 | Is assaying autoantibodies useful for diagnosing early rheumatoid arthritis? |
| Q37771781 | Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. |
| Q35555003 | Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression |
| Q45924953 | Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. |
| Q38055244 | Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy |
| Q89808044 | Measuring ACPA in the general population or primary care: is it useful? |
| Q36577538 | Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis |
| Q36099553 | Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis? |
| Q51740730 | Modulation of inflammatory arthritis by gut microbiota through mucosal inflammation and autoantibody generation. |
| Q33665938 | Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists [...] |
| Q36993245 | Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis. |
| Q37998089 | New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis |
| Q39799883 | Organising pneumonia as the first manifestation of rheumatoid arthritis |
| Q89820667 | Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System |
| Q61797542 | Overlap of Characteristic Serological Antibodies in Rheumatoid Arthritis and Wheat-Related Disorders |
| Q37435917 | PADI4 haplotypes in association with RA Mexican patients, a new prospect for antigen modulation |
| Q40329877 | Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis |
| Q40119794 | Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis |
| Q38211488 | Pharmacology of intra-articular triamcinolone |
| Q38101678 | Platelets and autoimmunity. |
| Q35637484 | Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis |
| Q35760017 | Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope |
| Q51056063 | Predictive factors related to progression toward rheumatoid arthritis in Korean patients with undifferentiated arthritis. |
| Q45137792 | Presence and role of anti-citrullinated protein antibodies in experimental arthritis models |
| Q36955351 | Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project |
| Q39886098 | Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis |
| Q37671218 | Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations. |
| Q80625456 | Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study |
| Q95383075 | Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist |
| Q47120186 | Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis |
| Q40160018 | Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. |
| Q33664464 | RETRACTED: Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis |
| Q35637041 | Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset |
| Q36594248 | Recent advances in the genetics of rheumatoid arthritis |
| Q37155766 | Rheumatoid Arthritis: Early diagnosis and treatment outcomes. |
| Q26747512 | Rheumatoid Arthritis: The Stride from Research to Clinical Practice |
| Q35638299 | Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis |
| Q34250833 | Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis |
| Q51716351 | Serum IgG activity against cyclic citrullinated peptide in patients evaluated for rheumatoid factor correlates with the IgM isotype. |
| Q36027446 | Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate |
| Q51804775 | Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis. |
| Q42560891 | Smoking and nicotine exposure delay development of collagen-induced arthritis in mice |
| Q35636886 | Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles |
| Q38166204 | Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases |
| Q37882064 | Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future |
| Q52370705 | Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues. |
| Q80632492 | Testing for antibodies to cyclic citrullinated peptides and rheumatoid factor--what is best for early RA? |
| Q50129712 | The B cell response to citrullinated antigens in the development of rheumatoid arthritis. |
| Q42369919 | The Infectious Basis of ACPA-Positive Rheumatoid Arthritis. |
| Q33873663 | The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment |
| Q36805269 | The association of anti-CCP antibodies with disease activity in rheumatoid arthritis |
| Q36425074 | The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis |
| Q38975179 | The autoimmunity-oral microbiome connection |
| Q37972090 | The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome |
| Q38212757 | The clinical significance of posttranslational modification of autoantigens |
| Q36624577 | The complex role of Fcgamma receptors in the pathology of arthritis |
| Q86414594 | The diagnostic utility of matrix metalloproteinase-3 and high-sensitivity C-reactive protein for predicting rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-negative patients with recent-onset undifferentiated arthritis |
| Q36475622 | The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression |
| Q36787712 | The immune response to citrullinated proteins in patients with rheumatoid arthritis: genetic, clinical, technical, and epidemiological aspects |
| Q37980340 | The influence of ACPA status and characteristics on the course of RA. |
| Q42598147 | The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens |
| Q34027412 | The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis |
| Q38206946 | The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. |
| Q42956395 | The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis. |
| Q24799403 | The role and clinical implications of G6PI in experimental models of rheumatoid arthritis |
| Q57667231 | The role of IL-17-secreting mast cells in inflammatory joint disease |
| Q50308665 | The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis |
| Q61452098 | The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis |
| Q26865606 | The use and abuse of diagnostic/classification criteria |
| Q37710782 | The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis |
| Q87111600 | Tryptase is a candidate autoantigen in rheumatoid arthritis |
| Q35881995 | Update on autoantibodies in rheumatoid arthritis |
| Q52854962 | Use of prognostic markers in early rheumatoid arthritis to identify patients at risk of destructive disease. |
| Q33604889 | Validation of Leiden Score in Predicting Progression of Rheumatoid Arthritis in Undifferentiated Arthritis in Indian Population |
| Q43223531 | Validation of a prediction rule for the diagnosis of rheumatoid arthritis in patients with recent onset undifferentiated arthritis |
| Q79988181 | [Autoantibody profile in rheumatoid arthritis] |
| Q79926612 | [Diagnostic use of autoantibodies] |
| Q83398657 | [Early arthritis: action desired - treatment required] |
| Q81575718 | [Early diagnosis of rheumatoid arthritis] |
| Q80148345 | [Laboratory diagnostics of systemic autoimmune diseases. Part II: rheumatoid arthritis and vasculopathies] |
| Q36098311 | cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis. |
Search more.